ASA’s Post

🚨 Injured by Dangerous Drugs? You Deserve Justice! 🚨 If you or someone you love has suffered due to dangerous or defective drugs, you're not alone. Our dedicated team of attorneys is here to help you fight back. We specialize in representing individuals who have been harmed by unsafe medications, ensuring they receive the compensation and justice they deserve. 🔍 What We Offer: Expert legal representation with a focus on drug-related injuries A thorough understanding of pharmaceutical law and patient rights Compassionate, personalized service for each client A strong track record of holding big pharmaceutical companies accountable Visit our website to learn more: www.costaivone.com #DrugSafety #LegalSupport #InjuryLaw #PharmaceuticalInjury #JusticeSeekers

Life Science Law invites you to join our latest Webinar, please register on the link below to save your spot. Topic: Marketing of Pharmaceutical Drugs & Interactions with Healthcare Professionals in a Digital Era https://lnkd.in/djcc2fiW 📅 Date: Friday, 12th April 2024   ⏰ Time: 12pm (GMT)   🎙️ Co-Speakers: Wendy, Founder & Samantha, Senior Legal Consultant     Join us to unravel:  ◾ How interactions are sought.     ◾ How consent is obtained and documented.      ◾ Ensuring content remains of a high standard and is relevant.     ◾ The volume of communication is appropriate.    Get in touch! Is there an aspect of this subject that you would like covered? What would you ask Wendy and Samantha? Let us know.     #webinar #industryinsights #pharmamarketing #healthcare  

📢💡 The next edition of 𝐃𝐁𝐒 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐋𝐞𝐠𝐚𝐥 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 – a subjective review of European and Polish life sciences law news prepared by DBS Lawyers – is now available.   ✅ This time we present the latest CJEU rulings on the revocation of provisional measures and access to personal data, a summary of the enforcement of EU competition law in the pharmaceutical sector, as well as the latest changes to Polish law on pharmacy acquisitions.   Click below for more details. Enjoy reading! ⤵ #pharmaceuticals #healthcare #lifescience #DBSlawfirm

May the colors of Holi paint your life with joy, prosperity and endless moments of celebration. Wishing you and loved one a vibrant and happy Holi! At BioRatna we provide end-to-end AI integrated consultancy services to Pharma and Biotech companies, globally. Our services include Pharmacovigilance, Medical Writing, Clinical Trials, Repurposing, IP filings, Patent & Trademark Registration. Call us on +91-9428360877 or connect via email info@bioratna.com #healthcare #Dhuleti2024 #service #researchanddevelopment #futuretrends #pharma #pharmaceuticals #pharmacovigilance #regulatory #complaince #clinical #clinicalresearch #intellectualproperty #patent #trademark #intellectualpropertyrights #clinicaltrials

One interesting angle in the Qvar RediHaler litigation is whether the FTC will have the will and wherewithal to participate in cases (e.g., as intervenor or amicus) involving drug patents that the agency previously claimed to have been wrongfully listed. #DrugDevelopment, #Pharmaceuticals, #ClinicalTrials, #DrugDiscovery, #InnovationInResearch, #Bioscience, #IntegratedDrugDevelopment, #PatientSafety, #ScientificAdvancements, #BiomedicalTesting, #DrugRepurposing, #pharma, #patent, #patents, #patentlitigation, #patentlaw, #ftc, #genericdrugs, #generics, #genericmedicines

The document to be published tomorrow by the U.S. regarding march-in rights for approved drugs won't have any immediate force. The document is only a draft, and the enabling provisions of the Bayh-Dole Act contain ambiguities sure to produce years of litigation in response to the government’s first exercise of any such rights. #DrugDevelopment, #Pharmaceuticals, #ClinicalTrials, #DrugDiscovery, #InnovationInResearch, #Bioscience, #IntegratedDrugDevelopment, #PatientSafety, #ScientificAdvancements, #BiomedicalTesting, #DrugRepurposing, #pharma, #patent, #patents

🌿Japan’s first #medicalcannabis law may end up only legalising a single #pharmaceuticalproduct, while also criminalising #recreationalcannabis consumption. The country could soon have its first medical #cannabis regulation in place, allowing in theory for the use of #cannabinoid-based approved medical drugs: the new bill is expected to come into effect by the end of 2024. 👀Stay informed: https://ow.ly/pzSC50Q9UIa #hemp #medicinalcannabis #cannabisproducts #cannabisindustry #cannabisregulation

Six months into the first year of the Inflation Reduction Act’s Drug Price Negotiation Program, the “negotiations” and legal challenges there to continue to play out. Join Brian Burgess, Appellate and Supreme Court Litigation partner and co-chair of our FDA litigation practice, Alexandra Lu, IP Litigation partner and Big Molecule Watch editor, and Matt Wetzel, Life Sciences Regulatory & Compliance partner and co-chair of our Late-Stage Drug Development practice, for a webinar updating on the various legal challenges to the Inflation Reduction Act’s Drug Price Negotiation Program and the status of the ongoing “negotiations” for the first ten drugs selected into the program. Register today! #InflationReductionAct #DrugPriceNegotiationProgram

Is your organization preparing to launch a psychedelic drug clinical trial? This branch of medicine is seeing an explosion of funding and research, but it presents unique challenges, especially when it comes to legal matters. Since these trials include a pharmaceutical and psychological component, covering all of your bases is essential. In this article, Kimberly Chew, senior counsel at Husch Blackwell, provides an in-depth overview of the most important legal considerations to ensure compliance and success. Set a few minutes aside to dive in. It’s worth the read! Source: https://hubs.li/Q026cp2t0 #clinicaltrials #psychedelics #regulatoryguidelines #protips #regulations #psychedelicsubstances #legalconsiderations

Our latest report on Drug Repurposing & Repositioning in Europe is out now! 🎉 Download your copy now and unlock the potential of drug repurposing. 💼 https://lnkd.in/ecptm4Sa In collaboration with industry experts from NLO | European patent and trademark attorneys, 3D-PharmXchange, and the REPO4EU consortium, we've delved deep into the regulatory framework and patent opportunities surrounding drug repurposing. 💡 Covering major topics such as off-patent products and new indications, our report provides invaluable insights into protecting the results of repurposing programs. 💊 Discover effective strategies to prevent others from benefiting from new indications, navigate regulatory challenges, and ensure proper alignment between clinical trials and IP filings. 🚀 Whether you're aiming to benefit patients or create economic value, our report highlights the key to success: staying in control of your program's results by establishing exclusivity. 💼 Barend Bouma Jaap Mannaerts Bianca Pauly #DrugRepurposing #IPStrategy #Pharmaceuticals #RegulatoryFramework #PatentOpportunities